Drug
Fianlimab clinical trials
Also written REGN3767.
- studies test it
- 27
- open now
- 18
- in phase 3
- 5
- first study started
- 2010
Keep track of what changes. Save the fianlimab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Combined with it in one product
Studies by the year they started
26 studies that test it; most in 2026 (9); 1 more planned to start later
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2016 | 1 |
| 2022 | 1 |
| 2023 | 4 |
| 2024 | 5 |
| 2025 | 5 |
| 2026 | 9 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 1
- Phase 2
- 23
- Phase 3
- 5
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 10 · Other 17
Regeneron Pharmaceuticals (10) · Memorial Sloan Kettering Cancer Center (3) · University of Chicago (2) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (2) · University of California, Irvine (1) · M.D. Anderson Cancer Center (1) · Mayo Clinic (1) · Brian Rini (1)
Often tested with
Tested in the same studies.
Cemiplimab (16) · Pembrolizumab (2) · Ipilimumab (2) · Marlotamig (1) · Trebananib (1) · Trastuzumab (1) · Ado-Trastuzumab Emtansine (1) · Pertuzumab (1)
Studies
Open first, then newest update. How each study uses fianlimab is read from its arms, and is right about nine times in ten.
Testing it · 27
- A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaRecruitingPhase 2Regeneron PharmaceuticalsNCT06769698Written as FDC fianlimab+cemiplimab
- A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With MelanomaRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT06594991Written as Fianlimab
- A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)RecruitingPhase 3Regeneron PharmaceuticalsNCT06246916Written as fianlimab
- Cemiplimab and Fianlimab Before Surgery for the Treatment of Stage IB-IIIB Non-Small Cell Lung CancerRecruitingPhase 2Mayo ClinicNCT06918132Written as Fianlimab
- Fianlimab&Cemiplimab as TotalNeoadj The (TNT) ForMelanomaNot yet recruitingPhase 2University of California, IrvineNCT07527325Written as Fianlimab
- A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)RecruitingPhase 2Brian RiniNCT07188896Written as Fianlimab
- Trial Assessing Fianlimab Plus Cemiplimab Plus Chemotherapy or Cemiplimab Plus Chemotherapy in Patients With Pleural MesotheliomaRecruitingPhase 2Intergroupe Francophone de Cancerologie ThoraciqueNCT07234058Written as Fianlimab
- Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal CancerRecruitingPhase 2Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT07281768Written as Fianlimab
- A Study Comparing Two Immunotherapy Options for Human Papillomavirus Positive HPV-Positive Head and Neck Cancer After TreatmentRecruitingPhase 2University of ChicagoNCT07179315Written as cemiplimab+fianlimab
- A Study to Learn About the Long-Term Health of Adult Participants From a Previous Study of a New Melanoma TreatmentEnrolling by invitationPhase 2Regeneron PharmaceuticalsNCT06848088Written as Fianlimab+cemiplimab
- Cemiplimab With or Without Fianlimab to Treat Older Patients With Localized or Locally Advanced MSI-H Colorectal CancerRecruitingPhase 2Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT06205836Written as Fianlimab
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerRecruitingPhase 2QuantumLeap Healthcare CollaborativeNCT01042379Written as Cemiplimab plus REGN3767
- PROSECCO: A Phase 2, Single Arm, Neoadjuvant Study Evaluating Combination Cemiplimab, Fianlimab, And Ipilimumab In Patients With Surgically Resectable MelanomaNot yet recruitingPhase 2M.D. Anderson Cancer CenterNCT07511036Written as Fianlimab
- A Study of Cemiplimab and Fianlimab in People With Clear Cell Renal Cell CarcinomaRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT06699602Written as Fianlimab
- Cemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in Clear Cell Renal Cell CarcinomaRecruitingPhase 2University of OklahomaNCT07223541Written as Fianlimab 1600 MG Intravenous Solution
- A Trial of Locoregionally Advanced Squamous Cell Carcinoma of The Head and NeckNot yet recruitingPhase 2University of ChicagoNCT07346196Written as Fianlimab
- Encorafenib and biNimetinib Followed by CEmiplimab and FiAnLimab in Patients With BRAF Mutant melanOma and Symptomatic Brain MetastasesRecruitingPhase 2Grupo Español Multidisciplinar de MelanomaNCT06887088Written as cemiplimab+fianlimab
- Gemcitabine/Cisplatin Plus Cemiplimab With or Without Fianlimab in Localized Muscle-invasive Bladder Cancer (NeoSTOP-IT)RecruitingPhase 2Columbia UniversityNCT06571708Written as Fianlimab
- A Study of Radiation Therapy and Cemiplimab With or Without Fianlimab In People With Bladder CancerWithdrawnPhase 2Memorial Sloan Kettering Cancer CenterNCT07414992Written as Cemiplimab and Fianlimab
- A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With SurgeryActive, not recruitingPhase 2Regeneron PharmaceuticalsNCT06161441Written as Fianlimab
See all 27 studies that test fianlimab →
Given in every arm · 8 — fianlimab is usual care beside what is tested
- Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian CancerRecruitingPhase 2Regeneron PharmaceuticalsNCT06787612Written as Fianlimab
- A Study Comparing Cemiplimab-based Treatments for Adult Participants With Locally Advanced Basal Cell Skin Cancer (laBCC)Not yet recruitingPhase 2Regeneron PharmaceuticalsNCT07808515Written as Fianlimab
- A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care TreatmentsRecruitingPhase 1Regeneron PharmaceuticalsNCT05137054Written as Fianlimab
- A Safety and Efficacy Study of Combined Fianlimab + Cemiplimab in Children and Young Adults With Recurrent or Progressive High-Grade Glioma or Posterior Fossa-A EpendymomaNot yet recruitingPhase 1/2Regeneron PharmaceuticalsNCT07567469Written as Cemiplimab+Fianlimab Fixed Dose Combination (FDC)
- Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung CancerRecruitingPhase 2Montefiore Medical CenterNCT06865339Written as Fianlimab
- Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate CancerActive, not recruitingPhase 1/2University of Wisconsin, MadisonNCT04989946Written as Fianlimab
- Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult PatientsActive, not recruitingPhase 2Regeneron PharmaceuticalsNCT03916627Written as fianlimab
- Safety and Pharmacokinetics of Cemiplimab Anti-programmed Death-ligand 1 (Anti-PD-1) and Other Agents in Japanese Adult Patients With Advanced MalignanciesActive, not recruitingPhase 1Regeneron PharmaceuticalsNCT03233139Written as Fianlimab
As the comparator · 2 — what is tested is compared with fianlimab
- A Phase II Platform Study to Evaluate Treatment With Cemiplimab Monotherapy or Cemiplimab Plus Fianlimab or Other Novel Combinations in Patients With Colorectal Cancer With Minimal Residual Disease Following Definitive Surgery and Chemotherapy (EMPIRE)RecruitingPhase 2NSABP Foundation IncNCT07058012Written as cemiplimab plus fianlimab
- A Study of Cemiplimab and Fianlimab in People With Nasopharyngeal CarcinomaNot yet recruitingPhase 1Memorial Sloan Kettering Cancer CenterNCT07650266Written as Fianlimab
Codes
What other systems call fianlimab · ClinicalTrials.gg INT017509
- UNII (FDA) OX5LRQ5H6KFIANLIMABOne source FDA
- NCI Thesaurus C132339FianlimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | OX5LRQ5H6K | FIANLIMAB | One source FDA |
| NCI Thesaurus | C132339 | Fianlimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.